Block listing Interim Review
1 December 2016 16:00
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 1 DECEMBER 2016
| Name of applicant: | ASTRAZENECA PLC | |||
| Name of scheme: | ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME | |||
| Period of return: | From: | 31 MAY 2016 | To: | 30 NOVEMBER 2016 |
| Balance of unallotted securities under scheme(s) from previous return: | 4,065,743 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 478,408 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 3,587,335 | |||
| Name of contact: | MARTIN BENNETT |
| Telephone number of contact: | 07825 530066 |
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
| Media Enquiries | ||
| Neil Burrows | UK/Global | +44 203 749 5637 |
| Vanessa Rhodes | UK/Global | +44 203 749 5736 |
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Jacob Lund | Sweden | +46 8 553 260 20 |
| Michele Meixell | US | +1 302 885 2677 |
| Investor Relations | ||
| Thomas Kudsk Larsen | +44 203 749 5712 | |
| Craig Marks | Finance, Fixed Income, M&A | +44 7881 615 764 |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Mitchell Chan | Oncology | +1 240 477 3771 |
| Lindsey Trickett | Cardiovascular & Metabolic Diseases | +1 240 543 7970 |
| Nick Stone | Respiratory | +44 203 749 5716 |
| Christer Gruvris | Autoimmunity, neuroscience & infection | +44 203 749 5711 |
| US toll free | +1 866 381 7277 |
Adrian Kemp
Company Secretary, AstraZeneca PLC
-ENDS-